Cargando…

Can nirmatrelvir/ritonavir treatment shorten the duration of COVID-19 isolation?

BACKGROUND: The impact of nirmatrelvir/ritonavir treatment on shedding of viable virus in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unclear. METHODS: A prospective cohort study evaluating mildly ill COVID-19 patients was conducted. Virologic responses were compared between nirm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Haein, Yang, Jeong-Sun, Ko, Jae-Hoon, Lee, Myungsun, Lee, Joo-Yeon, Park, Sehee, Kim, Jun-Won, Shin, Younmin, Lee, Jung-Min, Na, Yoo Jin, Park, Byoung Kwon, Kim, Hyungjin, Lee, Young Ho, Yang, Jinyoung, Huh, Kyungmin, Cho, Sun Young, Kang, Cheol-In, Chung, Doo Ryeon, Peck, Kyong Ran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596971/ https://www.ncbi.nlm.nih.gov/pubmed/36314031 http://dx.doi.org/10.3389/fmed.2022.988559

Ejemplares similares

Short-Term Effectiveness of Oral Nirmatrelvir/Ritonavir Against the SARS-CoV-2 Omicron Variant and Culture-Positive Viral Shedding
por: Lee, Eunyoung, et al.
Publicado: (2023)

Nirmatrelvir-ritonavir for COVID-19
por: McDonald, Emily G, et al.
Publicado: (2022)

Clinical Utility of Sero-Immunological Responses Against SARS-CoV-2 Nucleocapsid Protein During Subsequent Prevalence of Wild-Type, Delta Variant, and Omicron Variant
por: Lee, Beomki, et al.
Publicado: (2023)

Augmented humoral and cellular immunity against severe acute respiratory syndrome coronavirus 2 after breakthrough infection in kidney transplant recipients who received 3 doses of coronavirus disease 2019 vaccine
por: Yang, Jinyoung, et al.
Publicado: (2023)

1106. Comparison of Diagnostic Power of Conventional Culture and Automated Blood Culture System with Pleural Fluid
por: Ho Lee, Young, et al.
Publicado: (2023)

Real-World Effectiveness of Nirmatrelvir-Ritonavir and Its Acceptability in High-Risk COVID-19 Patients
por: Kim, Min-Kyung, et al.
Publicado: (2023)

212. Effectiveness of Empirical Piperacillin/tazobactam Compared to Cefepime for Bloodstream Infection Caused by Gram-Negative Bacilli
por: Ho Lee, Young, et al.
Publicado: (2023)

Benefits of nirmatrelvir–ritonavir remain unproven for some populations
por: McDonald, Emily G., et al.
Publicado: (2022)

Nirmatrelvir and ritonavir for COVID-19
Publicado: (2022)

Clinical Features and Outcomes of Invasive Fusariosis: A Case Series in a Single Center with Literature Review
por: Kim, Ji-Yeon, et al.
Publicado: (2023)

Association nirmatrelvir/ritonavir contre la COVID-19
por: McDonald, Emily G., et al.
Publicado: (2022)

523. Efficacy and Safety of Nirmatrelvir/Ritonavir for COVID-19 in Adolescents
por: Lee, Kiriam Escobar, et al.
Publicado: (2023)

Characteristics and Clinical Outcomes of Extended-Spectrum beta-lactamase-producing Klebsiella pneumoniae Bacteremia in Cancer Patients
por: Nham, Eliel, et al.
Publicado: (2020)

Nirmatrelvir/Ritonavir Prescription Rate and Outcomes in Coronavirus Disease 2019: A Single Center Study
por: Park, Jin Ju, et al.
Publicado: (2022)

Effectiveness and Adverse Events of Nirmatrelvir/Ritonavir Versus Molnupiravir for COVID-19 in Outpatient Setting: Multicenter Prospective Observational Study
por: Park, Jin Ju, et al.
Publicado: (2023)

Sequence type 17 is a predictor of subsequent bacteremia in vancomycin-resistant Enterococcus faecium-colonized patients: a retrospective cohort study
por: Kim, Si-Ho, et al.
Publicado: (2021)

228. Early Recurrent Postoperative Bloodstream infections in Living-Donor Liver Transplant Recipients
por: Kim, Si-Ho, et al.
Publicado: (2019)

Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?
por: Hung, Yuan-Pin, et al.
Publicado: (2022)

Nirmatrelvir Plus Ritonavir: First Approval
por: Lamb, Yvette N.
Publicado: (2022)

Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections
por: Yang, Jinyoung, et al.
Publicado: (2023)

Inpatient remdesivir versus nirmatrelvir-ritonavir in the progression of COVID-19
por: Patel, Dimple, et al.
Publicado: (2023)

1701. Differences in Diagnostic Performance of β-d-Glucan Testing in Patients with Varying Degrees of Susceptibility to Invasive Fungal Infections
por: Nham, Eliel, et al.
Publicado: (2019)

Comparison of 16S Ribosomal RNA Targeted Sequencing and Culture for Bacterial Identification in Normally Sterile Body Fluid Samples: Report of a 10-Year Clinical Laboratory Review
por: Yoo, In Young, et al.
Publicado: (2020)

449. Elevated Lactate Dehydrogenase in Convalescent Severe COVID-19 Patients Reflects Delayed Clinical Recovery and Activated Th(1) and Th(17) Responses
por: Yang, Jinyoung, et al.
Publicado: (2023)

Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19
por: Lu, Jiayue, et al.
Publicado: (2023)

Role of echocardiography in uncomplicated Staphylococcus aureus catheter-related bloodstream infections
por: Mun, Seok Jun, et al.
Publicado: (2021)

Effect of short-term corticosteroid use on reactogenicity and immunogenicity of the first dose of ChAdOx1 nCoV-19 vaccine
por: Yang, Jinyoung, et al.
Publicado: (2021)

Effects of Short-Term Corticosteroid Use on Reactogenicity and Immunogenicity of the First Dose of ChAdOx1 nCoV-19 Vaccine
por: Yang, Jinyoung, et al.
Publicado: (2021)

Invasive Fungal Diseases in Kidney Transplant Recipients: Risk Factors for Mortality
por: Seok, Hyeri, et al.
Publicado: (2020)

Treatment of acute tacrolimus toxicity with phenytoin after Paxlovid (nirmatrelvir/ritonavir) administration in a kidney transplant recipient
por: Kwon, Eun-Jeong, et al.
Publicado: (2022)

Possible medication error risks with nirmatrelvir+ritonavir
Publicado: (2022)

Correction to: Nirmatrelvir Plus Ritonavir: First Approval
por: Lamb, Yvette N.
Publicado: (2022)

Difference in the Clinical Outcome of Bloodstream Infections Caused by Klebsiella aerogenes and Enterobacter cloacae Complex
por: Jeon, Minji, et al.
Publicado: (2021)

Drug Interactions With Nirmatrelvir-Ritonavir in Older Adults Using Multiple Medications
por: Ross, Sydney B., et al.
Publicado: (2022)

Pharmacokinetic/pharmacodynamic parameters of vancomycin for predicting clinical outcome of enterococcal bacteremia
por: Nham, Eliel, et al.
Publicado: (2022)

Clinical characteristics of COVID-19 rebound after nirmatrelvir-ritonavir or molnupiravir therapy: A prospective cohort study
por: Han, Jaijun, et al.
Publicado: (2023)

483. Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with Hemodialysis
por: Li, Xin, et al.
Publicado: (2023)

Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir
por: Wong, Grace Lai-Hung, et al.
Publicado: (2022)

Impact of vancomycin use trend change due to the availability of alternative antibiotics on the prevalence of Staphylococcus aureus with reduced vancomycin susceptibility: a 14-year retrospective study
por: Kang, Yu Ri, et al.
Publicado: (2022)

Nirmatrelvir–Ritonavir and Viral Load Rebound in Covid-19
por: Anderson, Annaliesa S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_18cg2rfmvuvoqndq5dmrggbhcc